WO2022063190A1 - 吡嗪硫联苯基类化合物及其应用 - Google Patents
吡嗪硫联苯基类化合物及其应用 Download PDFInfo
- Publication number
- WO2022063190A1 WO2022063190A1 PCT/CN2021/119985 CN2021119985W WO2022063190A1 WO 2022063190 A1 WO2022063190 A1 WO 2022063190A1 CN 2021119985 W CN2021119985 W CN 2021119985W WO 2022063190 A1 WO2022063190 A1 WO 2022063190A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- added
- reaction
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 404
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title abstract 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 108
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 36
- 238000004808 supercritical fluid chromatography Methods 0.000 claims description 36
- 230000014759 maintenance of location Effects 0.000 claims description 22
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 18
- 238000004458 analytical method Methods 0.000 claims description 18
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 238000000926 separation method Methods 0.000 claims description 14
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000001569 carbon dioxide Substances 0.000 claims description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- GHQPBDDZGPAVJP-UHFFFAOYSA-N azanium;methanol;hydroxide Chemical compound N.O.OC GHQPBDDZGPAVJP-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 225
- 239000000243 solution Substances 0.000 description 115
- 238000006243 chemical reaction Methods 0.000 description 97
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 76
- 239000012043 crude product Substances 0.000 description 76
- 238000003786 synthesis reaction Methods 0.000 description 72
- 230000015572 biosynthetic process Effects 0.000 description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 62
- 239000012074 organic phase Substances 0.000 description 60
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 47
- 238000004440 column chromatography Methods 0.000 description 47
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- 239000002904 solvent Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 36
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 36
- 229910052757 nitrogen Inorganic materials 0.000 description 34
- 239000000203 mixture Substances 0.000 description 33
- 239000012071 phase Substances 0.000 description 32
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 22
- 239000003208 petroleum Substances 0.000 description 22
- 150000004675 formic acid derivatives Chemical class 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 229910000027 potassium carbonate Inorganic materials 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- -1 inorganic acid salts Chemical class 0.000 description 17
- 238000002390 rotary evaporation Methods 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 229910021529 ammonia Inorganic materials 0.000 description 14
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 235000019253 formic acid Nutrition 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 238000013375 chromatographic separation Methods 0.000 description 8
- 210000003722 extracellular fluid Anatomy 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000012224 working solution Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000012295 chemical reaction liquid Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 6
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000002977 intracellular fluid Anatomy 0.000 description 5
- 210000001853 liver microsome Anatomy 0.000 description 5
- 230000003228 microsomal effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 102000004257 Potassium Channel Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 108010021848 cyclosomatostatin Proteins 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 108020001213 potassium channel Proteins 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- DZANYXOTJVLAEE-UHFFFAOYSA-N 6,8-difluoro-4-methylumbelliferyl phosphate Chemical compound FC1=C(OP(O)(O)=O)C(F)=CC2=C1OC(=O)C=C2C DZANYXOTJVLAEE-UHFFFAOYSA-N 0.000 description 2
- LLENVBUPWUQAGL-UHFFFAOYSA-N 6,8-difluoro-7-hydroxy-4-methylcoumarin Chemical compound FC1=C(O)C(F)=CC2=C1OC(=O)C=C2C LLENVBUPWUQAGL-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- AKGGYBADQZYZPD-UHFFFAOYSA-N benzylacetone Chemical compound CC(=O)CCC1=CC=CC=C1 AKGGYBADQZYZPD-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000002038 chemiluminescence detection Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 2
- 229960000203 propafenone Drugs 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ASVYXWZOBCRSFB-UHFFFAOYSA-N C(C)S(=O)(O)=S.OCCN1CCNCC1 Chemical compound C(C)S(=O)(O)=S.OCCN1CCNCC1 ASVYXWZOBCRSFB-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150048674 PTPN11 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- DORMTBIPKNPJPY-UHFFFAOYSA-N acetic acid;iodobenzene Chemical compound CC(O)=O.IC1=CC=CC=C1 DORMTBIPKNPJPY-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000004730 hepatocarcinogenesis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000044858 human PTPN11 Human genes 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Definitions
- the present invention relates to pyrazinethiobiphenyl compounds and their application, in particular to the compound of formula (II) or a pharmaceutically acceptable salt thereof.
- Shp2 SH2 domain-containing protein-tyrosine phosphatase-2
- PTP protein tyrosine phosphatase
- PTPN11 gene which can not only positively regulate the downstream signal transduction pathway through the catalytic activity of phosphatase, but also play a positive regulatory role as a phosphatase-independent adaptor protein, and can also play a positive role in specific conditions. It has a negative regulatory effect, and thus widely participates in the regulation of biological functions such as cell differentiation, migration, and related signal transduction processes.
- PTPN11 mutation is considered to be a high-risk factor for juvenile myelomonocytic leukemia (JMML). At the same time, it is considered to be the proto-oncogene of leukemia because of the abnormal activation and mutation of Shp2 in different types of leukemia.
- Shp2 In cancer, pancreatic cancer, gastric cancer and glioma, Shp2 has also been reported to be overactivated; in lung cancer, Shp2 acts as an oncogene to promote tumor occurrence and development by regulating various mechanisms. But in the process of hepatocarcinogenesis, Shp2 plays the role of tumor suppressor gene under the influence of specific environment. In conclusion, as an important node molecule, Shp2 plays an important regulatory role in the process of tumorigenesis and development, and is a potential therapeutic target.
- the present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof,
- E 1 is O or CH 2 ;
- T 1 is N or CH
- R 11 , R 13 and R 14 are each independently C 1-3 alkyl
- R 12 is H or C 1-3 alkyl
- R 2 is F, Cl, Br or I
- R 3 is C 1-3 alkyl optionally substituted with 1 , 2 or 3 R a ;
- R 4 is H, F, Cl, Br, I or C 1-3 alkyl optionally substituted with 1 , 2 or 3 R b ;
- Ra and Rb are each independently F, Cl, Br, I, OH or NH2 ;
- n 0, 1, 2 or 3;
- n 1, 2 or 3;
- n 1, 2 or 3
- the structural unit for the structural unit Structural units for
- the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof,
- R 11 , R 13 and R 14 are each independently C 1-3 alkyl
- R 12 is H or C 1-3 alkyl
- R 2 is F, Cl, Br or I
- R 3 is C 1-3 alkyl optionally substituted with 1 , 2 or 3 R a ;
- R 4 is H, F, Cl, Br, I or C 1-3 alkyl optionally substituted with 1 , 2 or 3 R b ;
- Ra and Rb are each independently F, Cl, Br, I, OH or NH2 ;
- n 1, 2 or 3.
- R 11 , R 13 and R 14 are each independently CH 3 , and other variables are as defined in any technical solution of the present invention.
- R 12 is H or CH 3 , and other variables are as defined in any technical solution of the present invention.
- R 3 is CH 3 , and other variables are as defined in any technical solution of the present invention.
- R 4 is F, Cl, Br or I, and other variables are as defined in any technical solution of the present invention.
- the above compound has the structure of formula (II-1)
- the above-mentioned compound has the structure of formula (I-1) or (I-2)
- the above compound has the structure of formula (I-1A), (I-1B), (I-2A), (II-1A) or (II-1B)
- n, m, E 1 , T 1 , R 11 , R 12 , R 13 , R 14 , R 2 , R 3 and R 4 are as defined in any technical solution of the present invention.
- the above-mentioned compound has the structure of formula (I-1A-1), (I-2A-1), (II-1A-1) or (II-1B-1)
- the present invention also provides the following compounds or pharmaceutically acceptable salts thereof,
- the above-mentioned compound of the present invention is compound 004,
- the compound of the present invention is a stereoisomer of compound 004 or a formate of the stereoisomer, and the stereoisomer or its formate is subjected to chiral supercritical fluid chromatography
- the retention time after analysis is 3.1-3.5min, preferably 3.2-3.4min, more preferably about 3.3min; the conditions for the chiral supercritical fluid chromatography analysis are: chromatographic column: Chiralpak AS-3 (100mm*4.6mm, 3 ⁇ m) ; Mobile phase: carbon dioxide; [0.05% triethylamine, % ethanol]: 40% ⁇ 40%.
- the above-mentioned compound of the present invention is another stereoisomer of compound 004, and the retention time of the stereoisomer after analysis by chiral supercritical fluid chromatography is 4.3-4.7min, preferably 4.4-4.6min , more preferably about 4.5min; the conditions for the chiral supercritical fluid chromatography analysis are: chromatographic column: Chiralpak AS-3 (100mm*4.6mm, 3 ⁇ m); mobile phase: carbon dioxide; [0.05% triethylamine, ethanol% ]: 40% ⁇ 40%.
- the compound of the present invention is a stereoisomer of compound 005; the retention time of the stereoisomer after analysis by chiral supercritical fluid chromatography is 4.8-5.2min, preferably 4.9-5.1min, more Preferably about 5.0min; the conditions of the chiral supercritical fluid chromatography analysis are: chromatographic column: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-ethanol]; ethanol%: 48%-78 %,7min.
- the compound of the present invention is another stereoisomer of compound 005; the retention time of the stereoisomer after analysis by chiral supercritical fluid chromatography is 5.6-6.0min, preferably 5.7-5.9min, More preferably about 5.8min; the conditions for the chiral supercritical fluid chromatography analysis are: chromatographic column: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-ethanol]; ethanol%: 48%- 78%, 7min.
- the above compound is a stereoisomer of compound 006, and the retention time of the stereoisomer after separation by chiral supercritical fluid chromatography is 4.9-5.3min, preferably 5.0-5.2min, more preferably about 5.1min;
- the conditions for the chiral supercritical fluid chromatographic separation are: chromatographic column: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-methanol]; methanol %: 40%-40%.
- the above compound is another stereoisomer of compound 006, and the retention time of the stereoisomer after separation by chiral supercritical fluid chromatography is 6.6-7.0min, preferably 6.7-6.9min, more Preferably about 6.8min;
- the conditions for the chiral supercritical fluid chromatographic separation are: chromatographic column: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-methanol]; methanol %: 40%-40 %.
- the compound of the present invention is a stereoisomer of compound 007; the retention time of the stereoisomer after separation by chiral supercritical fluid chromatography is 6.6-7.0 min, preferably 6.7-6.9 min, more Preferably about 6.8min; the conditions for the chiral supercritical fluid chromatographic separation are chromatographic column: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-ethanol]; ethanol%: 48%-78% ,10min.
- the compound of the present invention is another stereoisomer of compound 007; the retention time of the stereoisomer after separation by chiral supercritical fluid chromatography is 7.1-7.5min, preferably 7.2-7.4min , more preferably about 7.4min; the conditions for the chiral supercritical fluid chromatographic separation are chromatographic column: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-ethanol]; ethanol%: 48%- 78%, 10min.
- the compound of the present invention is another stereoisomer of compound 008; the retention time of the stereoisomer after separation by chiral supercritical fluid chromatography is 3.6-4.0min, preferably 3.7-3.9min , more preferably about 3.9min; the conditions for the chiral supercritical fluid chromatographic separation are: chromatographic column: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-ethanol]; ethanol%: 45% -45%.
- the compound of the present invention is a stereoisomer of compound 010; the retention time of the stereoisomer after separation by chiral supercritical fluid chromatography is 2.3-2.7min, preferably 2.4-2.6min, more Preferably about 2.6min; the conditions for the chiral supercritical fluid chromatographic separation are: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-ethanol]; ethanol%: 40%-40%.
- the compound of the present invention is another stereoisomer of compound 010; the retention time of the stereoisomer after separation by chiral supercritical fluid chromatography is 3.2-3.6min, preferably 3.3-3.5min , more preferably about 3.4min; the conditions for the chiral supercritical fluid chromatographic separation are: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-ethanol]; ethanol%: 40%-40% .
- the second aspect of the present invention also provides a pharmaceutical composition, which comprises the compound defined in any of the above technical solutions or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- the present invention also provides a method for treating a disease associated with SHP2 in a subject in need thereof, comprising providing the subject with an effective dose of a compound as defined in any of the above technical solutions or a pharmaceutically acceptable salt or pharmaceutical combination thereof thing.
- the present invention also provides the use of the above compound, its isomer or its pharmaceutically acceptable salt or pharmaceutical composition in preparing a medicine for treating SHP2-related diseases.
- the compounds of the present invention exhibit good inhibitory activity on protein tyrosine phosphatase SHP2, and will have excellent therapeutic effect in patients with abnormal SHP2 tumors.
- the term "pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissue , without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- salts refers to salts of the compounds of the present invention, prepared from compounds with specific substituents discovered by the present invention and relatively non-toxic acids or bases.
- base addition salts can be obtained by contacting such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts.
- acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts including, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-toluenesulfonic, citric, tartaric, and methanesulfonic acids; also include salts of amino acids such as arginine, etc. , and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain both basic and acidic functional groups and thus can be converted into either base
- the pharmaceutically acceptable salts of the present invention can be synthesized from the acid or base containing parent compound by conventional chemical methods. Generally, such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of the two.
- the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and racemic mixtures thereof and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which belong to this within the scope of the invention.
- Additional asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.
- enantiomers or “optical isomers” refer to stereoisomers that are mirror images of each other.
- cis-trans isomer or “geometric isomer” result from the inability to rotate freely due to double bonds or single bonds to ring carbon atoms.
- diastereomer refers to a stereoisomer in which the molecule has two or more chiral centers and the molecules are in a non-mirror-image relationship.
- tautomer or “tautomeric form” refers to isomers of different functional groups that are in dynamic equilibrium at room temperature and can rapidly interconvert.
- a chemical equilibrium of tautomers can be achieved if tautomers are possible (eg, in solution).
- proton tautomers also called prototropic tautomers
- Valence tautomers include interconversions by recombination of some bonding electrons.
- keto-enol tautomerization is the interconversion between two tautomers, pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
- atoms with "*" or “#” are chiral atoms or chiral centers that exist as (R) or (S) as a single enantiomer or in enriched form; for example, expressed as
- the terms “enriched in one isomer”, “enriched in isomers”, “enriched in one enantiomer” or “enriched in one enantiomer” refer to one of the isomers or pairs
- the enantiomer content is less than 100%, and the isomer or enantiomer content is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or Greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.
- isomeric excess or “enantiomeric excess” refer to the difference between two isomers or relative percentages of two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomeric excess (ee value) is 80% .
- Optically active (R)- and (S)-isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting mixture of diastereomers is separated and the auxiliary group is cleaved to provide pure desired enantiomer.
- a diastereomeric salt is formed with an appropriate optically active acid or base, followed by conventional methods known in the art
- the diastereoisomers were resolved and the pure enantiomers recovered.
- separation of enantiomers and diastereomers is usually accomplished by the use of chromatography employing a chiral stationary phase, optionally in combination with chemical derivatization (eg, from amines to amino groups) formate).
- the compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound.
- compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I) or C-14 ( 14 C).
- deuterated drugs can be formed by replacing hydrogen with deuterium, and the bonds formed by deuterium and carbon are stronger than those formed by ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs can reduce toxic side effects and increase drug stability. , enhance the efficacy, prolong the biological half-life of drugs and other advantages. All transformations of the isotopic composition of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.
- substituted means that any one or more hydrogen atoms on a specified atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence of the specified atom is normal and the substituted compound is stable.
- oxygen it means that two hydrogen atoms are substituted. Oxygen substitution does not occur on aromatic groups.
- any variable eg, R
- its definition in each case is independent.
- the group may optionally be substituted with up to two Rs, with independent options for R in each case.
- combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
- substituents When a substituent is vacant, it means that the substituent does not exist. For example, when X in A-X is vacant, it means that the structure is actually A. When the listed substituents do not indicate through which atom it is attached to the substituted group, such substituents may be bonded through any of its atoms, for example, pyridyl as a substituent may be through any one of the pyridine ring The carbon atom is attached to the substituted group.
- the direction of attachment is arbitrary, for example,
- the linking group L in the middle is -MW-, at this time -MW- can connect ring A and ring B in the same direction as the reading order from left to right. It is also possible to connect ring A and ring B in the opposite direction to the reading order from left to right.
- Combinations of the linking groups, substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
- any one or more sites in the group can be linked to other groups by chemical bonds.
- connection method of the chemical bond is not located, and there is an H atom at the linkable site, when the chemical bond is connected, the number of H atoms at the site will be correspondingly reduced with the number of chemical bonds connected to the corresponding valence. the group.
- the chemical bond connecting the site to other groups can be represented by straight solid line bonds straight dotted key or wavy lines Express.
- a straight solid bond in -OCH 3 indicates that it is connected to other groups through the oxygen atom in this group;
- the straight dashed bond in the group indicates that it is connected to other groups through the two ends of the nitrogen atom in the group;
- the wavy line in the phenyl group indicates that it is connected to other groups through the 1 and 2 carbon atoms in the phenyl group;
- C 1-3 alkyl is used to denote a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms.
- the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups, etc.; it can be monovalent (eg methyl), divalent (eg methylene) or multivalent (eg methine) .
- Examples of C1-3 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
- Cn-n+m or Cn - Cn+m includes any particular instance of n to n+ m carbons, eg C1-12 includes C1 , C2 , C3, C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , and C 12 , also including any one range from n to n+m, eg C 1-12 includes C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12 , etc.; in the same way, n yuan to n +m-membered means that the number of atoms in the ring is from n to n+m, for example, 3-12-membered ring includes 3-membered ring, 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, 8-membered
- leaving group refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction (eg, a nucleophilic substitution reaction).
- a substitution reaction eg, a nucleophilic substitution reaction
- representative leaving groups include triflate; chlorine, bromine, iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonic acid Esters, etc.; acyloxy, such as acetoxy, trifluoroacetoxy, and the like.
- protecting group includes, but is not limited to, "amino protecting group", “hydroxy protecting group” or “thiol protecting group”.
- amino protecting group refers to a protecting group suitable for preventing side reactions at the amino nitrogen position.
- Representative amino protecting groups include, but are not limited to: formyl; acyl groups, such as alkanoyl groups (eg, acetyl, trichloroacetyl, or trifluoroacetyl); alkoxycarbonyl groups, such as tert-butoxycarbonyl (Boc) ; Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); Arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di -(4'-Methoxyphenyl)methyl; silyl groups such as trimethylsilyl (TMS) and tert-
- hydroxy protecting group refers to a protecting group suitable for preventing hydroxyl side reactions.
- Representative hydroxy protecting groups include, but are not limited to: alkyl groups such as methyl, ethyl and tert-butyl; acyl groups such as alkanoyl (eg acetyl); arylmethyl groups such as benzyl (Bn), p-methyl Oxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl groups such as trimethylsilyl (TMS) and tert-butyl Dimethylsilyl (TBS) and the like.
- alkyl groups such as methyl, ethyl and tert-butyl
- acyl groups such as alkanoyl (eg acetyl)
- arylmethyl groups such as benzyl (Bn), p-methyl Oxybenzyl (PMB), 9-fluorenyl
- supercritical fluid chromatography for example, supercritical fluid chromatography (chromatographic column: DAICEL CHIRALPAK AS (250mm*30mm, 10 ⁇ m); mobile phase: [0.1% ammonia water-ethanol]; ethanol%: 48%- 78%, 7min, where 7min represents the time required to increase the ethanol concentration from 48% to 78%.
- chromatographic column: DAICEL CHIRALPAK AS 250mm*30mm, 10 ⁇ m
- mobile phase [0.1% ammonia water-ethanol]
- ethanol% 48%- 78%, 7min, where 7min represents the time required to increase the ethanol concentration from 48% to 78%.
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by their combination with other chemical synthesis methods, and those well known to those skilled in the art Equivalent to alternatives, preferred embodiments include, but are not limited to, the embodiments of the present invention.
- the structure of the compound of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art.
- SXRD single crystal X-ray diffractometry
- the cultivated single crystal is collected by Bruker D8venture diffractometer
- the light source is CuK ⁇ radiation
- the scanning method is as follows: After scanning and collecting relevant data, the crystal structure was further analyzed by the direct method (Shelxs97), and the absolute configuration could be confirmed.
- the solvent used in the present invention is commercially available.
- the present invention adopts the following abbreviations: aq represents water; eq represents equivalent, equivalent; NaCNBH 3 represents sodium cyanoborohydride; rt represents room temperature; mp represents melting point; DCM represents dichloromethane; MeOH represents methanol; Critical fluid chromatography; MMS indicates hepatic intrinsic clearance.
- Step 1 Synthesis of Compound 001-2:
- compound 001-2 (5 g, 15.76 mmol, 1 eq) and dimethylphosphine oxide (1.23 g, 15.76 mmol, 1 eq) were dissolved in dioxane (50 mL), and tris(dioxane) was added in one portion.
- the concentrate was dissolved in 30 mL of water and 50 mL of ethyl acetate, and the layers were extracted while the aqueous phase was extracted three times with ethyl acetate (30 mL, 30 mL, 30 mL).
- the organic phases were combined, washed once with saturated sodium chloride solution (30 mL), and finally the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- compound 001-3 (2.3g, 8.60mmol, 1eq) and compound 001-3A (2.25g, 10.32mmol, 1.2eq) were dissolved in dioxane (25mL), and N,N was added at one time -Diisopropylethylamine (3.33g, 25.80mmol, 4.49mL, 3eq), Tris(dibenzylideneacetone)dipalladium (787.38mg, 859.86 ⁇ mol, 0.1eq), 4,5-bisdiphenylphosphine -9,9-Dimethylxanthene (497.53 mg, 859.86 ⁇ mol, 0.1 eq), then the temperature was raised to 110° C.
- compound 001-5 (270 mg, 1.22 mmol, 1 eq) and compound 001-5A (382.59 mg, 1.84 mmol, 1.5 eq) were dissolved in dioxane (3 mL), and tris(dibenzylidene) was added at one time acetone) dipalladium (112.05mg, 122.36 ⁇ mol, 0.1eq), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (70.80mg, 122.36 ⁇ mol, 0.1eq), N,N - Diisopropylethylamine (474.43 mg, 3.67 mmol, 639.40 ⁇ L, 3 eq), then warmed to 110° C.
- Step 1 Synthesis of Compound 002-1:
- compound 001-1 (200 mg, 968.68 ⁇ mol, 1 eq) was dissolved in acetonitrile (5 mL), and diiodomethane (73.00 mg, 774.94 ⁇ mol, 69.52 ⁇ L, 0.8 eq) was added at one time, and the temperature was raised to 60 °C, tert-Butyl nitrite (149.83 mg, 1.45 mmol, 172.82 ⁇ L, 1.5 eq) was slowly added, then the temperature was raised to 80° C. and stirred for 1 hour. The reaction solution was concentrated under reduced pressure at 43°C.
- compound 002-2 (1 g, 3.72 mmol, 1 eq) and compound 001-3A (894.37 mg, 4.10 mmol, 1.1 eq) were dissolved in dioxane (10 mL), and diisopropyl group was added at one time Ethylamine (1.44g, 11.17mmol, 1.95mL, 3eq), tris(dibenzylideneacetone)dipalladium (340.98mg, 372.36 ⁇ mol, 0.1eq), 4,5-bisdiphenylphosphine-9,9- Dimethylxanthene (215.45 mg, 372.36 ⁇ mol, 0.1 eq) was then heated to 110° C. and stirred for 5 hours.
- the reaction liquid was cooled to 20°C, and concentrated under reduced pressure at 43°C.
- the concentrate was dissolved in 50 mL of water and 50 mL of ethyl acetate, and the layers were extracted while the aqueous phase was extracted three times with ethyl acetate (50 mL, 30 mL, 30 mL).
- the organic phases were combined, washed once with saturated sodium chloride solution (30 mL), and finally the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- Column chromatography The crude product was isolated by column chromatography (0-10% methanol in dichloromethane). Compound 002-3 was obtained.
- Step 5 Synthesis of Compound 002-5:
- compound 002-4 50 mg, 225.50 ⁇ mol, 1 eq
- compound 001-5A 70.51 mg, 338.25 ⁇ mol, 1.5 eq
- the concentrate was dissolved in 30 mL of water and 30 mL of ethyl acetate, and the layers were extracted, while the aqueous phase was extracted three times with ethyl acetate (30 mL ⁇ 3).
- the organic phases were combined, washed once with saturated sodium chloride solution (30 mL), and finally the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- the crude product was isolated by column chromatography (0-10% methanol in dichloromethane). Compound 002-5 was obtained. MS (ESI) m/z: 348.9 [M+H]+.
- compound 002-5 50 mg, 143.16 ⁇ mol, 1 eq
- compound 001-6A 39.29 mg, 143.16 ⁇ mol, 1 eq
- dimethylacetamide 2 mL
- water 2 mL
- Potassium carbonate 59.36 mg, 429.48 ⁇ mol, 3 eq
- the reaction solution was directly spin-dried to obtain compound 002-6.
- Step 1 Synthesis of Compound 003-1:
- compound 002-2 (1.9 g, 7.07 mmol, 1 eq) was dissolved in N,N-dimethylformamide (20 mL), and sodium hydride (424.45 mg, 10.61 mmol, 60%) was added in one portion at 0°C. Purity, 1.5eq), the mixture was stirred at 0°C for 10min, then iodomethane (2.01g, 14.15mmol, 880.86 ⁇ L, 2eq) was added and the temperature was raised to 25°C and stirred for hours. The reaction solution was added dropwise to 10 mL of ice water, diluted with 50 mL of ethyl acetate, and the solution was separated.
- compound 003-1 (1.5 g, 5.31 mmol, 1 eq) and compound 001-3A (1.27 g, 5.84 mmol, 1.1 eq) were dissolved in dioxane (20 mL), and diiso was added at one time Propylethylamine (2.06g, 15.92mmol, 2.77mL, 3eq), tris(dibenzylideneacetone)dipalladium (486.08mg, 530.81 ⁇ mol, 0.1eq), 4,5-bisdiphenylphosphine-9, 9-Dimethylxanthene (307.14 mg, 530.81 ⁇ mol, 0.1 eq), then warmed to 110° C.
- Step 3 Synthesis of Compound 003-3:
- compound 003-3 (56 mg, 237.54 ⁇ mol, 1 eq) and compound 001-5A (74.27 mg, 356.30 ⁇ mol, 1.5 eq) were dissolved in dioxane (3 mL), and diisopropyl group was added in one portion.
- Ethylamine (92.10mg, 712.61 ⁇ mol, 124.12uL, 3eq), Tris(dibenzylideneacetone)dipalladium (21.75mg, 23.75 ⁇ mol, 0.1eq), 4,5-bisdiphenylphosphine-9,9- Dimethylxanthene (13.74 mg, 23.75 ⁇ mol, 0.1 eq) was then heated to 110° C. and stirred for 5 hours. The reaction liquid was cooled to 20°C, and concentrated under reduced pressure at 43°C.
- the concentrate was dissolved in 30 mL of water and 30 mL of ethyl acetate, and the layers were extracted, while the aqueous phase was extracted three times with ethyl acetate (30 mL ⁇ 3).
- the organic phases were combined, washed once with saturated sodium chloride solution (30 mL), and finally the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- the crude product was isolated by column chromatography (0-10% methanol in dichloromethane) to give compound 003-4. MS (ESI) m/z: 362.9 [M+H] + .
- Step 1 Synthesis of Compound 004-2:
- compound 004-1 (5.0 g, 19.43 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (60 mL), replaced with nitrogen three times and then cooled to -78°C.
- anhydrous tetrahydrofuran 60 mL
- To the reaction mixture was slowly added dropwise a solution of lithium diisopropylamide (2.0 M, 10.69 mL, 1.1 eq) in tetrahydrofuran, the mixture was stirred at -78°C for 1 hour, and then compound 004-2A in tetrahydrofuran was slowly added dropwise to the system The solution was reacted at -78°C for 30 minutes, and then the reaction system was slowly warmed to -25°C for 15 hours.
- compound 004-2 (6.91 g, 18.91 mmol, 1 eq) was dissolved in dioxane (80 mL) and methanol (32 mL), and then sodium hydroxide aqueous solution (6 M, 16 mL, 5.08 eq) was added. Then, the temperature was raised to 100°C and the reaction was refluxed for 15 hours. After the reaction was completed, it was cooled to room temperature, the organic solvent was removed under reduced pressure, and the pH was adjusted to 3-4 with dilute hydrochloric acid (1.0M), filtered, and the filter cake was washed with water.
- dioxane 80 mL
- methanol 32 mL
- sodium hydroxide aqueous solution 6 M, 16 mL, 5.08 eq
- compound 004-4 (2g, 6.26mmol, 1eq) and compound 004-5A (2.28g, 18.79mol, 3.0eq) were added to a single-neck flask, followed by tetraethyl titanate (5mL) 100
- the reaction was refluxed at °C for 18 hours. After the reaction was completed, it was cooled to room temperature, the mixture was poured into ice water to quench, ethyl acetate (50 mL) was added, and the mixture was stirred for 1 hour, and the layers were separated. The aqueous phase was extracted with ethyl acetate (50 mL ⁇ 3).
- Step 8 Synthesis of Compound 004:
- Step 9 Synthesis of Compounds 004-8A and 004-8B:
- Compound 004-8 was sent to chiral supercritical fluid chromatography for separation (chromatographic column: Chiralpak AS-3 (100mm*4.6mm, 3 ⁇ m); mobile phase: carbon dioxide; [0.05% triethylamine, ethanol%]: 40%- 40%), two isomers were separated, and isomer 1 was 004-8A (retention time 2.557 min). MS (ESI) m/z: 637.1 [M+H] + . Isomer 2 was 004-8B (retention time 3.028 min), MS (ESI) m/z: 637.1 [M+H] + .
- Step 10 Synthesis of Compound 004A:
- Step 1 Synthesis of Compound 005-2:
- Step 1 Synthesis of Compound 006-3:
- compound 006-3 (12.00 g, 30.21 mmol, 1 eq) was dissolved in a mixed solution of NN dimethylacetamide (100 mL) and water (10 mL), and dichlorobis[di-tert-butyl] was added.
- the system was purged with nitrogen three times, The temperature was raised to 130°C for 5 hours.
- reaction solution was cooled to room temperature, 150 ml of water was added, extracted with ethyl acetate (200 mL ⁇ 3), the organic phases were combined, concentrated under reduced pressure to a concentrated solution volume of about 150 mL, washed with water 4 times, washed with saturated brine 2 times, and anhydrous Dry over sodium sulfate and concentrate under reduced pressure to obtain crude product.
- the crude product was separated by column chromatography (30%-35% ethyl acetate in petroleum ether) to obtain compound 006-4, MS (ESI) m/z: 263.9 [M+H] + .
- reaction solution was cooled to room temperature, the reaction solution was added to ice water, stirred for 40 minutes, the supernatant was added to a separatory funnel, and then ethyl acetate was added for extraction (200 mL ⁇ 3), and the organic phases were combined and used Washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product.
- the crude product was isolated by column chromatography (25%-35% ethyl acetate in petroleum ether) to give compound 006-5. MS(ESI) m/z: 322.9 [M- tBu ] + .
- Step 1 Synthesis of Compound 007-2:
- Step 1 Synthesis of Compound 008-2:
- compound 008-2 (12.00 g, 30.21 mmol, 1 eq) was dissolved in a mixed solution of NN dimethylacetamide (100 mL) and water (10 mL), and dichlorobis[di-tert-butyl] was added.
- the system was purged with nitrogen three times, The temperature was raised to 130°C for 5 hours.
- reaction solution was cooled to room temperature, 150 ml of water was added, extracted with ethyl acetate (200 mL ⁇ 3), the organic phases were combined, concentrated under reduced pressure to a concentrated solution volume of about 150 ml, washed with saturated brine (200 mL ⁇ 6), and anhydrous sulfuric acid. Dry over sodium and concentrate under reduced pressure to give crude product.
- the crude product was isolated by column chromatography (30%-35% ethyl acetate in petroleum ether) to give 008-3, MS (ESI) m/z: 264.1 [M- t Bu] + .
- Step 1 Synthesis of Compound 009-3:
- reaction solution was cooled to room temperature, 150 ml of water was added, extracted with ethyl acetate (200 mL ⁇ 3), the organic phases were combined, concentrated under reduced pressure to a concentrated solution volume of about 150 ml, washed with saturated brine (200 mL ⁇ 6), and anhydrous sulfuric acid. Dry over sodium and concentrate under reduced pressure to give crude product.
- the crude product was isolated by column chromatography (30%-35% ethyl acetate in petroleum ether) to give 009-6, MS (ESI) m/z: 290.1 [M- t Bu] + .
- 009-6 (4.2g, 12.16mmol, 1eq) was dissolved in tetraethyl titanate (100mL), 004-5A (4.42g, 36.48mmol, 3eq) was added, the system was purged with nitrogen three times, and then heated to 130°C The reaction was carried out for 3 hours.
- reaction solution was cooled to room temperature, the reaction solution was added to ice water, stirred for 40 minutes, the supernatant was added to a separatory funnel, and then ethyl acetate was added for extraction (200 mL ⁇ 3), and the organic phases were combined and used Washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product.
- the crude product was isolated by column chromatography (10%-20% ethyl acetate in petroleum ether) to give compound 009-7. MS (ESI) m/z: 449.1 [M+H] + .
- Step 7 Synthesis of Compound 009-10A:
- Step 8 Synthesis of Compound 009A:
- Step 9 Synthesis of Compound 009-9B:
- Step 10 Synthesis of Compound 009-10B:
- Step 11 Synthesis of Compound 009B:
- reaction solution was cooled to room temperature, filtered, 200 mL of water was added to the filtrate, extracted with ethyl acetate (100 mL ⁇ 3), the organic phases were combined, washed with saturated brine (200 mL ⁇ 1), and the organic phase was dried over anhydrous sodium sulfate. , filtered, and the solvent was removed by rotary evaporation.
- the crude product was separated by flash column chromatography (3%-5% ethyl acetate in petroleum ether) to obtain compound 010-2.
- reaction solution was cooled to room temperature, 150 ml of water was added, extracted with ethyl acetate (200 mL ⁇ 3), the organic phases were combined, concentrated under reduced pressure to a concentrated solution volume of about 150 mL, washed with saturated brine (200 mL ⁇ 6) , dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product.
- HEPES hydroxyethylpiperazine ethanethiosulfonic acid
- EDTA ethylenediaminetetraacetic acid
- 75 mM KCl 75 mM NaCl
- 0.01% Brij-35 5 mM dithiothreitol (DTT) and 10 %DMSO (final).
- the compounds of the present invention have certain inhibitory activity on PTPN11/SHP2-FL.
- the purpose of this experiment is to verify the inhibitory effect of the compounds of the present invention on the proliferation of KRAS G12C-mutated NCI-H358 human non-small cell lung cancer cells.
- Cell line NCI-H358 (purchased from Proceedings), RPMI1640 medium, penicillin/streptomycin antibiotics were purchased from Vicente, and fetal bovine serum was purchased from Biosera.
- CellTiter-Glo Cell Viability Chemiluminescence Detection Reagent
- NCI-H358 cells were seeded in a white 96-well plate, 80 ⁇ L of cell suspension per well, which contained 4000 NCI-H358 cells. Cell plates were incubated overnight in a carbon dioxide incubator. The compounds to be tested were diluted 5-fold to the ninth concentration, that is, from 2000 ⁇ M to 5.12 nM, and a double-well experiment was set up. Add 78 ⁇ L of medium to the middle plate, and then transfer 2 ⁇ L of each well of the compound to the middle plate according to the corresponding position. After mixing, transfer 20 ⁇ L of each well to the cell plate. Compound concentrations transferred to cell plates ranged from 10 [mu]M to 0.026 nM. The cell plates were placed in a carbon dioxide incubator for 5 days.
- Another cell plate was prepared, and the signal value was read on the day of drug addition as the maximum value (Max value in the following equation) to participate in data analysis.
- the IC50 value can be obtained by curve fitting with four parameters ("log(inhibitor) vs.response in GraphPad Prism") --Variable slope" mode).
- Table 2 shows the results of the cell activity screening test of the compound H358 of the present invention.
- the compounds of the present invention have good inhibitory activity on H358 cells.
- Intravenous and oral vehicles are a certain proportion of hydroxypropyl ⁇ -cyclodextrin aqueous solution or physiological saline solution. Collect whole blood samples within 24 hours, centrifuge at 3000g for 15 minutes, separate the supernatant to obtain plasma samples, add 4 times the volume of acetonitrile solution containing the internal standard to precipitate the protein, centrifuge to take the supernatant, add an equal volume of water, and then centrifuge to take the supernatant.
- LC-MS/MS analysis method was used to quantitatively analyze the blood drug concentration, and the pharmacokinetic parameters, such as peak concentration, peak time, clearance rate, half-life, area under the drug-time curve, bioavailability, etc., were calculated.
- the compounds of the present invention can significantly improve the pharmacokinetics single or partial indexes in mice.
- the purpose of the research project was to use a 5-in-1 probe substrate of CYP isoenzymes to evaluate the inhibition of test articles against human liver microsomal cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4).
- HMM human liver microsomes
- the compounds of the present invention have weak inhibition on the five CYP isozymes.
- the full-automatic patch-clamp method was used to detect the effect of Example 1 to be tested on the hERG potassium channel.
- the cells stably expressing the hERG potassium channel used in the experiment were obtained from CHO-hERE of Aviva Biosciences, and CHO-hERG was cultured in 5% CO 2 at 37°C.
- CHO hERG medium is shown in Table 5.
- CHO-hERG cells ready for experiments were cultured for at least two days, and the cell density was above 75%. Before the experiment, cells were digested with TrypLE and then resuspended in extracellular fluid to collect cells.
- Extracellular fluid needs to be prepared once a month.
- the intracellular fluid must be aliquoted and stored at -20°C.
- the composition of intracellular and extracellular fluids is shown in Table 6.
- Extracellular fluid mM
- Intracellular fluid mM
- NaCl 145 - KCl 4 120 KOH - 31.25
- the compound to be tested and the positive control Amitriptyline were dissolved in DMSO into a stock solution of a certain concentration, then diluted according to different gradients, and finally added to the extracellular fluid according to a certain proportion to be diluted to the concentration to be tested. Visually inspect for the presence or absence of precipitation prior to the start of the experiment. Finally, in the test solution and the positive control Amitriptyline, the maximum concentration of DMSO should not exceed 0.3%.
- Hold the clamping potential at -80mv first give -50mv voltage stimulation for 80ms to record the cell leakage current value, then depolarize to +20mv, maintain 4800ms, open the hERG channel, and then repolarize to -50mv for 5000ms , elicited the hERG tail current and recorded, and finally, the voltage returned to the clamping potential -80mv and maintained for 3100ms.
- the above voltage stimulation was repeated every 15000ms.
- hERG QPatch HTX experiments were performed at room temperature. Whole cell protocols, voltage stimulation protocols and compound detection protocols were established on the software of QPatch Assay Software 5.2 (Sophion Bioscience).
- I (C) I b +(I fr -I b )*c n /(IC 50 n +c n )
- C is the compound test concentration
- n is the slope
- Curve fitting and inhibition rate calculation are both completed by Qpatch analysis software. If the inhibition rate at the lowest concentration exceeds half inhibition or the inhibition rate at the highest concentration does not reach half inhibition, the corresponding IC 50 of the compound is lower than the lowest concentration or IC 50 value. greater than the highest concentration.
- Human and animal microsomes were purchased from Corning or Xenotech and stored in a -80°C freezer.
- T60 incubation plate Prepare two 96-well incubation plates, named T60 incubation plate and NCF60 incubation plate respectively.
- stop solution 200ng/mL tolbutamide and 200ng/mL labetalol in acetonitrile
- Test sample MMS(mL/min/kg), H, M Formate salt of compound 004A 19.7, 67.9 Formate salt of compound 004B 33.0, 61.1 Compound 006A 31.2, 100.8 Compound 006B 47.9, 57.3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
化合物编号 | PTPN11/SHP2-FL(IC 50nM) |
化合物001的甲酸盐 | 21.8 |
化合物002的甲酸盐 | 12.6 |
化合物003的甲酸盐 | 72.4 |
化合物004的甲酸盐 | 2.84 |
化合物004A的甲酸盐 | 3.21 |
化合物004B的甲酸盐 | 2.61 |
化合物005A | 5.35 |
化合物005B | 3.66 |
化合物006A | 2.95 |
化合物006B | 2.22 |
化合物008A | 2.78 |
化合物008B | 2.43 |
化合物010A | 6.01 |
化合物010B | 5.81 |
化合物编号 | H358(IC 50nM) |
化合物004A的甲酸盐 | 56.5 |
化合物004B的甲酸盐 | 19.2 |
化合物006A | 30 |
化合物006B | 18 |
化合物010A | 11.9 |
化合物010B | 7.9 |
Reagent | Supplier | Catalog Number | Volume(mL) |
F12Hams | Invitrogen | 31765-092 | 500 |
FBS | Invitrogen | 10099-141 | 50 |
G418/Geneticin | Invitrogen | 10131-027 | 1 |
Hygromycin B | Invitrogen | 10687-010 | 1 |
组成成分 | 细胞外液(mM) | 细胞内液(mM) |
NaCl | 145 | - |
KCl | 4 | 120 |
KOH | - | 31.25 |
CaCl 2 | 2 | 5.374 |
MgCl 2 | 1 | 1.75 |
Glucose | 10 | - |
Na 2ATP | - | 4 |
HEPES | 10 | 10 |
EGTA | - | 10 |
pH | 7.4with NaOH | 7.2with KOH |
渗透压 | 295mOsm | 285mOsm |
供试样品 | hERG IC 50(nM) |
化合物004A的甲酸盐 | 8.20 |
化合物004B的甲酸盐 | 9.82 |
化合物006A | 10.3 |
化合物006B | 14.0 |
供试样品 | MMS(mL/min/kg),H,M |
化合物004A的甲酸盐 | 19.7,67.9 |
化合物004B的甲酸盐 | 33.0,61.1 |
化合物006A | 31.2,100.8 |
化合物006B | 47.9,57.3 |
Claims (22)
- 式(Ⅱ)化合物或其药学上可接受的盐,其中,E 1为O或CH 2;T 1为N或CH;R 11、R 13和R 14分别独立地为C 1-3烷基;R 12为H或C 1-3烷基;R 2为F、Cl、Br或I;R 3为C 1-3烷基,所述C 1-3烷基任选被1、2或3个R a取代;R 4为H、F、Cl、Br、I或C 1-3烷基,所述C 1-3烷基任选被1、2或3个R b取代;R a和R b分别独立地为F、Cl、Br、I、OH或NH 2;n为0、1、2或3;m为1、2或3;
- 根据权利要求1所述的化合物或其药学上可接受的盐,其中,R 11、R 13和R 14分别独立地为CH 3。
- 根据权利要求1所述的化合物或其药学上可接受的盐,其中,R 12为H或CH 3。
- 根据权利要求1所述的化合物或其药学上可接受的盐,其中,R 3为CH 3。
- 根据权利要求1所述的化合物或其药学上可接受的盐,其中,R 4为F、Cl、Br或I。
- 一种药物组合物,其包含权利要求1‐19任意一项所述的化合物或其药学上可接受的盐和药学上可接受的载体。
- 根据权利要求1~19任意一项所述化合物或其药学上可接受的盐或根据权利要求20所述的药物组合物在制备治疗与SHP2相关的疾病的药物中的应用。
- 根据权利要求21所述的应用,其中所述SHP2相关的疾病为实体瘤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180065019.2A CN116348466A (zh) | 2020-09-23 | 2021-09-23 | 吡嗪硫联苯基类化合物及其应用 |
TW111107823A TW202246279A (zh) | 2021-04-16 | 2022-03-03 | 吡𠯤硫聯苯基類化合物及其應用 |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011008309 | 2020-09-23 | ||
CN202011008309.7 | 2020-09-23 | ||
CN202110182212 | 2021-02-09 | ||
CN202110182212.6 | 2021-02-09 | ||
CN202110412812 | 2021-04-16 | ||
CN202110412812.7 | 2021-04-16 | ||
CN202110590591 | 2021-05-28 | ||
CN202110590591.2 | 2021-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022063190A1 true WO2022063190A1 (zh) | 2022-03-31 |
Family
ID=80844949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/119985 WO2022063190A1 (zh) | 2020-09-23 | 2021-09-23 | 吡嗪硫联苯基类化合物及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116348466A (zh) |
WO (1) | WO2022063190A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021148010A1 (zh) * | 2020-01-22 | 2021-07-29 | 南京明德新药研发有限公司 | 吡唑并杂芳环类化合物及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105916845A (zh) * | 2014-01-17 | 2016-08-31 | 诺华股份有限公司 | 用于抑制shp2活性的n-氮杂螺环烷取代的n-杂芳基化合物和组合物 |
CN107922388A (zh) * | 2015-06-19 | 2018-04-17 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
CN110143949A (zh) * | 2018-05-09 | 2019-08-20 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
WO2020063760A1 (en) * | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2020073949A1 (zh) * | 2018-10-10 | 2020-04-16 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
WO2020156243A1 (zh) * | 2019-01-31 | 2020-08-06 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
-
2021
- 2021-09-23 WO PCT/CN2021/119985 patent/WO2022063190A1/zh active Application Filing
- 2021-09-23 CN CN202180065019.2A patent/CN116348466A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105916845A (zh) * | 2014-01-17 | 2016-08-31 | 诺华股份有限公司 | 用于抑制shp2活性的n-氮杂螺环烷取代的n-杂芳基化合物和组合物 |
CN107922388A (zh) * | 2015-06-19 | 2018-04-17 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
CN110143949A (zh) * | 2018-05-09 | 2019-08-20 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
WO2020063760A1 (en) * | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2020073949A1 (zh) * | 2018-10-10 | 2020-04-16 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
WO2020156243A1 (zh) * | 2019-01-31 | 2020-08-06 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
Also Published As
Publication number | Publication date |
---|---|
CN116348466A (zh) | 2023-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022063190A1 (zh) | 吡嗪硫联苯基类化合物及其应用 | |
EP4166142A1 (en) | Methyl-substituted benzobisoxazole compound and use thereof | |
JP2022071072A (ja) | (s)-7-(1-アクリロイルピペリジン-4-イル)-2-(4-フェノキシフェニル)-4,5,6,7-テトラ-ヒドロピラゾロ[1,5-a]ピリミジン-3-カルボキサミドの結晶形、その調製、及びその使用 | |
JP2656702B2 (ja) | ペプチド性キヌクリジン | |
WO2021203768A1 (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
JP6948659B1 (ja) | ピリダジニルチアアゾールカルボキシアミド化合物 | |
WO2021148010A1 (zh) | 吡唑并杂芳环类化合物及其应用 | |
WO2010099698A1 (zh) | 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 | |
WO2020052647A1 (zh) | 作为lsd1抑制剂的杂螺环类化合物及其应用 | |
WO2022237797A1 (zh) | 烷基羧酸化合物及其应用 | |
KR20240004495A (ko) | 이소퀴놀론 화합물과 이의 용도 | |
JP7311207B2 (ja) | Mnk阻害剤としてのピロロトリアジン系化合物 | |
JP7374532B2 (ja) | 選択性の高いros1阻害剤としての化合物、及びその使用 | |
WO2021164742A1 (zh) | 喹啉类化合物 | |
WO2022156765A1 (zh) | 吡唑并吡嗪联三环类化合物及其应用 | |
WO2021139814A1 (zh) | 喹啉并咪唑类化合物及其应用 | |
JP7296017B2 (ja) | ベンゾスルタムを含む化合物 | |
WO2021004533A1 (zh) | 作为irak4和btk多靶点抑制剂的噁唑类化合物 | |
TW202246279A (zh) | 吡𠯤硫聯苯基類化合物及其應用 | |
WO2021164741A1 (zh) | 苯基双酰胺类化合物 | |
WO2022213935A1 (zh) | 噁二唑取代的螺环类化合物及其应用 | |
WO2022121900A1 (zh) | 吡咯并吡啶类化合物及其应用 | |
CN114945576B (zh) | 氘代噻吩并吡啶类化合物 | |
TW202246272A (zh) | 吡唑並吡嗪三環類化合物及其應用 | |
WO2022228365A1 (zh) | 六元杂芳并脲环的衍生物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21871559 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21871559 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 12.09.2023 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21871559 Country of ref document: EP Kind code of ref document: A1 |